Cognition Therapeutics files investor presentation with no material updates disclosed

COGNITION THERAPEUTICS INC

Filed an investor presentation under Item 7.01 for Regulation FD purposes.
Presentation slide titled 'Targeting Pathogenic Oligomers: A Disruptive Approach to Neurodegenerative Diseases'.
No financial results, pipeline milestones, or guidance changes are included in the filing.
Filing is a routine disclosure; no new material events reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.